Applying New Clinical Data to Practice: CCO Independent Conference of the 2021 Virtual ESMO Annual Meeting *

September 16-21, 2021; Virtual
Review experts’ conference preview commentary, Capsule Summary slidesets, and an expert analysis of key studies from the 2021 Virtual ESMO Congress.

Share

Program Content

Activities

VESPER
VESPER: Phase III Trial of Perioperative Chemotherapy With Dose-Dense MVAC vs Gemcitabine + Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2021

Expires: September 26, 2022

DESTINY-Breast03
DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated HER2+ Metastatic Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2021

Expires: September 22, 2022

Abiraterone + ADT in High-Risk M0 PCa
STAMPEDE Combined Analysis of ADT Plus Abiraterone Acetate + Prednisolone ± Enzalutamide vs ADT Alone in High-Risk Nonmetastatic Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2021

Expires: September 29, 2022

PEACE-1: OS in mCSPC
PEACE-1: Overall Survival With Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2021

Expires: September 26, 2022

CheckMate 649
CheckMate 649: Updated Results From Phase III Trial of First-line Nivolumab + CT or Ipilimumab vs CT in Advanced Gastroesophageal Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2021

Expires: September 27, 2022

TULIP
Phase III TULIP: vic-Trastuzumab Duocarmazine vs Physician’s Choice Treatment in Previously Treated HER2+ Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2021

Expires: September 27, 2022

KEYNOTE-355 Final Results
KEYNOTE-355: Randomized, Placebo-Controlled Phase III of Pembrolizumab + Chemotherapy in Previously Untreated Metastatic TNBC (Final Results)
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2021

EPOCH
EPOCH: Phase III Trial Comparing Transarterial Radioembolization With Yttrium-90 + Second-line CT vs CT Only in Patients With Unresectable Colorectal Liver Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2021

Expires: September 30, 2022

COSMIC-021: mCRPC Cohort
COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 21, 2021

Expires: September 20, 2022

DESTINY-Lung01: HER2mut Cohort
DESTINY-Lung01: Phase II Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2021

Expires: September 26, 2022

Dato-DXd in NSCLC With Mutations
Datopotamab Deruxtecan in Advanced NSCLC With Actionable Genomic Alterations: TROPION-Pan Tumor01 Phase I Trial Subset Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2021

Expires: September 29, 2022

DESTINY-Gastric02
DESTINY-Gastric02: Trastuzumab Deruxtecan in Western Patients With HER2+ Advanced Gastric or GEJ Cancer With Progression Following First-line Trastuzumab-Containing Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2021

Expires: September 21, 2022

CASPIAN: 3-Yr OS
CASPIAN: 3-Yr Survival Update of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2021

COSMIC-311 Final Analysis
COSMIC-311 Final Analysis: Phase III Trial of Cabozantinib vs Placebo in Radioiodine-Refractory Differentiated Thyroid Cancer After VEGFR TKI
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 29, 2021

Expires: September 28, 2022

VISION: HRQoL, Pain, Safety
VISION: HRQoL, Pain, and Safety Outcomes With 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 30, 2021

Expires: September 29, 2022

Activities

ESMO 2021: Preview
An Expert’s Guide to ESMO 2021: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: September 15, 2021

Expires: September 14, 2022

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.